Literature DB >> 4102573

Inactivation of influenza and other viruses by a mixture of virucidal compounds.

J S Oxford, C W Potter, C McLaren, W Hardy.   

Abstract

A mixture of benzalkonium chloride, Triton X100, and citric acid (Resiguard F) had a marked virucidal effect on lipid-containing deoxyribonucleic and ribonucleic acid viruses, such as vaccinia virus, herpesvirus, and influenza virus. Adenoviruses and picornaviruses were more resistant to inactivation. Electron microscopy showed that influenza particles became aggregated in the presence of Resiguard F and that the outer fringe of hemagglutinin and neuraminidase spikes seen in control virus preparations became indistinct. The mixture had no detectable antiviral activity in mice infected with influenza AO/PR/8/34 virus, and this was attributed to the reduced virucidal effect of Resiguard F in the presence of serum proteins.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4102573      PMCID: PMC377239          DOI: 10.1128/am.21.4.606-610.1971

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  13 in total

1.  Purification, N-terminal amino acid analysis, and disruption of an influenza virus.

Authors:  W G LAVER
Journal:  Virology       Date:  1961-08       Impact factor: 3.616

2.  Herpesvirus hominis encephalitis in Michigan. Report of thirteen cases, including six treated with idoxuridine.

Authors:  D C Nolan; M M Carruthers; A M Lerner
Journal:  N Engl J Med       Date:  1970-01-01       Impact factor: 91.245

3.  Prophylaxis of influenza with a synthetic isoquinoline.

Authors:  A S Beare; M L Bynoe; D A Tyrrell
Journal:  Lancet       Date:  1968-04-20       Impact factor: 79.321

4.  Field study of U.K.2054 against natural infection with A2-Hong Kong-68 influenza virus.

Authors:  P N Meenan; I B Hillary
Journal:  Lancet       Date:  1969-09-20       Impact factor: 79.321

5.  Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study.

Authors:  A W Galbraith; J S Oxford; G C Schild; G I Watson
Journal:  Lancet       Date:  1969-11-15       Impact factor: 79.321

6.  Electron microscope study of the viricidal properties of sodium magnesium-chlorophyllin.

Authors:  L B Mekler; A F Bychovsky; B L Krikun
Journal:  Nature       Date:  1969-05-10       Impact factor: 49.962

7.  Prophylaxis of smallpox with methisazone.

Authors:  D J Bauer; L St Vincent; C H Kempe; P A Young; A W Downie
Journal:  Am J Epidemiol       Date:  1969-08       Impact factor: 4.897

8.  Disruption of myxoviruses with Tween 20 and isolation of biologically active hemagglutinin and neuraminidase subunits.

Authors:  R G Webster; R W Darlington
Journal:  J Virol       Date:  1969-08       Impact factor: 5.103

9.  Degradation of influenza virus by non-ionic detergent.

Authors:  M J Corbel; C J Rondle; R G Bird
Journal:  J Hyg (Lond)       Date:  1970-03

10.  The antiviral and synergic actions of isatin thiosemicarbazone and certain phenoxypyrimidines in vaccinia infection in mice.

Authors:  D J BAUER
Journal:  Br J Exp Pathol       Date:  1955-02
View more
  4 in total

1.  Mechanism of inactivation of influenza viruses by immobilized hydrophobic polycations.

Authors:  Bryan B Hsu; Sze Yinn Wong; Paula T Hammond; Jianzhu Chen; Alexander M Klibanov
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

2.  Maturation of the Gag core decreases the stability of retroviral lipid membranes.

Authors:  Candice Davidoff; Riley J Payne; Sharon H Willis; Benjamin J Doranz; Joseph B Rucker
Journal:  Virology       Date:  2012-09-17       Impact factor: 3.616

3.  In vitro anti-influenza assessment of anionic compounds ascorbate, acetate and citrate.

Authors:  Hadiseh Shokouhi Targhi; Parvaneh Mehrbod; Fatemeh Fotouhi; Mehriar Amininasab
Journal:  Virol J       Date:  2022-05-23       Impact factor: 5.913

4.  Aminoadamantane-resistant strains of influenza A2 virus.

Authors:  J S Oxford; C W Potter
Journal:  J Hyg (Lond)       Date:  1973-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.